AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC

 AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC

AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC

Shots:

  • The P-III PACIFIC study involves assessing of Imfinzi vs PBO in patients with unresectable, Stage III, LA NSCLC whose disease had not progressed following concurrent platinum-based CRT.
  • The updated post-hoc analyses demonstrated OS @4yrs. (49.6% vs 36.3%), m-OS (47.5 vs 29.1mos); patients not progressed after 4yrs. (35% vs 19.5%) respectively, presented at ESMO
  • The company also highlights the data of Imfinzi vs CT in the P-III CASPIAN study underscoring the long-term benefit in patients with ES-SCLC. The exploratory subgroup analysis demonstrated PFS ≥12mos. (17% vs 4.5%), patients who were progression-free & had progression @1yr. (75% & 10%) chances of being alive @2yrs.respectively

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Print

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post